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Measurement  of cell-mediated cytotoxicity (CMC) 1 directed to cell surface 
antigens has  been  facilitated by the  elaboration of  a  relatively simple repro- 
ducible test in which ~lCr is released from labeled target cells (1-5). Other in- 
vestigators have examined  certain facets of the  test  (6-18)  and have  applied 
the technique to studies of tumor allograft systems (3-5, 16, 19, 20) and soluble 
antigens bound to the surface membrane of target cells (18, 21-26). 
The purpose of this study was to detect the appearance of cytotoxic lympho- 
cytes (CL) in spleens and draining lymph nodes of rats grafted with allogeneic 
skin by means of a  modified 51Cr release assay and to quantitate CMC  during 
rejection and prolonged survival of allografts induced by enhancing antibodies. 
With  5~Cr-labeled embryonic  fibroblasts  (EFB)  as  target  cells  derived  from 
donor strain rats that were the source of immunizing skin grafts, and with cyto- 
toxic lymphoid cells from sensitized recipients, the level of cellular immunity 
could be determined in recipients of skin allografts. 
Materials and Methods 
Anlmals.--150-2OO-g adult and neonatal Lewis (Le) rats were both used as skin-graft re- 
cipients and donors of aggressor cells for assays of CMC in vitro. Brown-Norway (BN) rats 
were a source of skin allografts and of target cells for CMC assays. Both inbred strains were 
obtained from our own breeding colony or from a commercial breeder (Simonsen Laboratories, 
Gilroy, Calif.). BN skin grafts, 1.5 cm on edge, were applied to the nuchal region of 7-8-day-old 
Le neonates  or to the axillae of adult Le rats. The latter were either normal, injected intra- 
peritoneally with 5 mg of cyclophosphamide 2 daily beginning 4 days before grafting, or neo- 
natally thymectomized 2448 hr after birth and used 100 or more days later. Completeness of 
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thymectomy was ascertained at the end of experiments by histologic examination of the tissue 
in the operative site. 
Antlsera and Antibodies.--Enhancing  antisera (EAS)  were prepared in Le adult rats that 
were grafted with skin two times and infused with spleen cells two times from BN donors. 
Complete details of preparation are presented in references 27 and 28. 0.3 ml of Le anti-BN 
(LABN) EAS or of normal Le serum (NLS) were injected intraperitoneally into experimental 
and control neonates, respectively, on the day of grafting. 
An IgG fraction was prepared from EAS; and for some experiments it was labeled with 125  I 
and enriched by adsorption to and elution from BN lymphocytes, as described previously (29). 
The enriched, labeled IgG (EIgG-125I)  with enhancing activity showed a specific binding of 
38% to BN spleen cells and 19% to BN embryonic fibroblasts (BN-EFB). 
Horse antiserum to rat thoracic duct cells (HARTD) 3 was precipitated two times with 50% 
(NH4)2SO4.  The  redissolved precipitate was passed over a  diethylaminoethyl (DEAE)-50 
Sephadex  column  (Pharmacia  Fine  Chemicals,  Inc.,  Uppsala,  Sweden)  equilibrated with 
phosphate-buffered saline  (PBS). The IgG was eluted, concentrated, and divided into two 
equal portions. Both were absorbed with rat erythrocytes and with NLS insolubilized  by 2.5% 
glutaraldehyde (30). One portion was further absorbed four times with 5 X  109 Le th~Taocytes 
and the other once with 109 Le bone marrow cells. HARTD IgG, absorbed with thymocytes, 
did not release any 51Cr from labeled BN-EFB. HARTD IgG absorbed with bone marrow 
cells released 50% of the isotope at a dilution of 1  : 16. 
Cytotoxic Lymphocytes  (CL) and  Target Cells.--Spleens  and  draining lymph nodes were 
removed aseptically from Le rats 3-13 days after placement of BN skin grafts or after subcuta- 
neous inoculation of 0.2 ml of incomplete Freund's adjuvant (control rats). Cell suspensions 
were prepared in Eagle's minimal essential medium (MEM), washed two times, and adjusted 
to a concentration of 2 X  107 ceils per milliliter. 
Peripheral blood lymphocytes  were collected from 10-12 ml of heparinized blood, as follows. 
The blood was incubated for 60 min at 37°C in sterile tissue culture flasks. An equal volume of 
3% Dextran 250 (Pharmacia Fine Chemicals, Inc.) in PBS was then added to the blood, and 
the mixture was incubated in plastic cylinders at 37°C for an additional 30 min. The super- 
natant was removed, mixed with cold MEM, and centrifuged for 15 rain at 1500 rpm. Red 
blood cells in the pellet were lysed with 0.83% ammonium chloride, which was removed by 
three washes of MEM. Mononuclear cells ranged from 5 to 10  X  107 cells per 10-12  ml of 
original blood sample, and were 96-98% of the total cell count. 
BN-EFB and Le-EFB were grown as monolayers in plastic tissue culture flasks from 12- 
14-day-old embryos that were minced and tr)~osinized. For use in CMC assays, the monolayers 
were flooded with 7.5 ml of trypsin ethylenediaminetetraacetate (EDTA)  solution (0.5 and 
0.2 mg/ml, respectively) for 10 min. The suspended cells were washed two times in 1ViEY[, and 
2 )<  107 cells were labeled with 200/zCi of Na~ 5I CrO44 by incubation for 30 min at 37°C in 
5% CO2 and 95% air. Suspensions were washed again four times and adjusted so that 50 #1 
contained 105 cells (20,000-25,000  cpm). 50 #1 of EFB were used as target cells. 
In one experiment, BN peritoneal exudate cells (BN-PEC) were used. They were flushed 
from the peritoneal cavity 3 days after intraperitoneal injection of 8 ml of sterile 10% proteose 
peptone, washed three times in MEM, and adjusted to a concentration of 2 X  107 cel]s/ml. 
They were labeled with 400-500  #Ci of Na25t  CrO4 as  described above. 50/zl contained 105 
cells (20,000 cpm) and were used as target cells. 
Cell-ik[edialed Cytotoxicity (CMC) Assay In  Vitro.--The method of Brunner et al.  (3) was 
slightly modified.  105 target cells were incubated with 107 aggressor lymphoid cells in 12 )< 75- 
A gift from Upjohn Co. Kalamazoo, Mich. 
4 International Chemical and Nuclear Corp., Irvine, Calif.  Specific activity, 400 mCi/mg 
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mm round-bottom  glass or plastic tissue culture tubes.  Volume was adjusted  to  1 ml with 
supplemented MEM. 5 The tubes were incubated for 2, 6, and 7.5 hr at 37°C in 5% CO2 and 
95% air on a rocking platform (8 tilts per min). Optimal incubation period was 7.5 hr, and  all 
data reported here are for this span of time unless otherwise noted. After incubation,  1 ml of 
MEM was added to each tube, tubes were centrifuged for 15 min at 1200 rpm, and  1 ml of 
supernatant was removed and counted for radioactivity. Maximal 51Cr release was obtained 
by lysis of target cells with 5% NP40 ° and was  87.9  4- 2.5% (SD) of SlCr input.  Each  test 
was run in four or five replicate samples, and  51Cr release is recorded as the mean of pooled 
cells from 2 to 3  control and experimental  animals or from  3  to  10 individual graft  recipi- 
ents for the kinetic studies. 
SlCr release with lymphoid cells -  spontaneous 51Cr release 
Specific 51Cr release  =  51Cr release with 5% NP40  --  spontaneous 51Cr release  )<  100. 
Mean spontaneous  51Cr release at 7.5 hr of incubation was  10.9 4-  1.1%  (so)  of 51Cr input 
(26 trials with BN-EFB) and 15.8 4- 1.8% (6 trials with BN-PEC). Tests in which the differ- 
ence between maximal 51Cr release minus spontaneous  6tCr release was less than 70~v  were 
discarded. 
In some experiments assays were carried out after preincubation of target cells with anti- 
bodies.  To each of five replicas, serial dilutions of heat-inactivated NLS, EAS, LABN-IgG 
(0.57 mg), or EIgG-125I  (10/zg), in 0.1-ml volumes of MEM, were added  105 51Cr BN-EFB 
cells. The mixtures were incubated for 30 min at 37°C. Immune or nonimmune aggressor cells 
were then added to each test tube, and volume was adjusted to 1 ml. Incubation was continued 
for 7.5 hr. In another study, 5  X  107 LABN aggressor cells were incubated in the following 
preparations for 45 rain at 37°C: 0.5 ml NLS; 0.5  mlLABNEAS;0.5 ml EIgG-I~sI (120 ng); 
0.5 ml HARTD IgG absorbed with bone marrow or thymus  cells (14 mg). Aggressor cells were 
washed two times in MEM, and 107 cells were distributed to each of five test tubes containing 
105  51Cr BN-EFB target cells. Incubation was continued for 7.5 hr.  When  complement  was 
used, it was added as fresh guinea pig serum diluted 1:2 in MEM. 
RESULTS 
CMC in Adult Le Rats wilh BN Skin Allografts.--A first series of experiments 
was designed to compare the effect of different kinds of grafting on the induction 
and expression of CMC  in adult Le rats  (Fig.  1). The most vigorous CMC  was 
elicited by first-set  BN  skin  and kidney grafts.  Intravenous  injections of allo- 
geneic  spleen  cells  failed  to  produce,  7  days  later,  significant  CMC.  Spleens 
from hyperimmune Le rats  that were immunized with two BN skin grafts  and 
two  intravenous  BN  spleen  cell  infusions  at  weekly  intervals  exhibited  less 
CMC  8  days  after  the last  immunizing  procedure  than  did spleens  of Le rats 
immunized with first-set BN  skin grafts. 
Specificity of CMC  for sensitizing AgB  antigens  was established  by demon- 
strating  that  LBNF1 spleen cells,  removed 7  days  after  a  BN  skin graft,  were 
not  cytotoxic  to  BN-PEC  (Fig.  1).  Similarly,  LABN  aggressor  cells  were 
unable  to  destroy  syngeneic  Le-EFB  (Fig.  2).  Also,  no  significant  release  of 
5 Contains 10~v heat-inactivated fetal calf serum; 4X nonessential amino acids; 1X gluta- 
rain; 100 units penicillin/ml; 2.5 ~g fungizone/ml; 100/~g streptomycin/ml; MgC12 X  6H20, 
0.002  m•/ml;  CaCl2, 0.0007  m~/ml. 
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5~Cr was observed when LABN aggressor cells were mixed with labeled Le-EFB 
and  unlabeled  BN-EFB.  Thus,  in  this  assay,  a  nonspecific toxic agent,  gen- 
erated by the interaction of immune aggressor ceils with specific AgB antigens, 
was not detected. More likely lysis of target cells was effected by a direct cell to 
cell reaction.  Specific 51Cr release increased with increasing ratios of aggressor 
to target cells over a  range of 10:1  to 200:1  (Fig. 3). Beyond a  ratio of 200:1, 
5~Cr release from target cells decreased. 
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FIG.  1.  C~IC after different immunization procedures.  Each point shows the specific ~lCr 
release from  10 a BN-PEC incubated with l07 Le or LBNFz spleen cells and represents the 
mean of four replicate samples of pooled cells from three rats, 4- 1 SD (vertical lines). Symbols: 
•  , first-set BN skin graft, 8 days before;  [], first-set BN kidney graft, 5 days before; •, two 
BN skin grafts, two BN spleen cell infusions, each 1 wk apart, 8 days after last injection; C), 
first-set BN skin graft on LBNF1 recipients, 8 days before;/k, 1 i. v. infusion  of 2  )<  l0 s BN 
spleen cells, 8  days before.  Shaded area: mean specific ~lCr release  4-  1 sD by normal Le 
spleen cells. 
A  kinetic study of CMC in the spleens and lymph nodes of grafted Le adult 
females was carried out (Fig. 4). CMC was first detected 5  days after grafting, 
in draining lymph nodes of graft recipients, and 1 day later in spleens of simi- 
larly prepared rats. Peak activity was constantly observed at 7 or 8 days, when 
rejection of the allogeneic skin was near completion.  (Median survival time in 
these  recipients was  7.5  i  0.7  days.)  CMC  dropped  quickly thereafter  and 
reached background levels in the lymph nodes on day 9, and in spleens on days 
10 and ll. 
CMC  in peripheral blood was also determined in a  second series of Le adult 
females grafted with  BN  skin  (Fig.  5).  CL  were first detected on  day  7,  and HANS-HARTMUT  PETER  AND  JOSEPH  D.  :FELDMAN  1305 
peaked on day 8, with a rapid return to background levels. The  curve depicted 
in Fig. 5 is similar to that of Fig. 4  and suggests that the rise and fall of CL in 
both the peripheral blood and the lymphoid tissues are temporally related. 
CMC in Atlografted  Le Neonates,  Cydophosphamide-Treated,  and Neonatally 
Thymectomized  Le Adult Rats.--Previous studies have demonstrated that in Le 
neonates and in cyclophosphamide-treated or neonatally thymectomized adult 
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FIG. 2.  Specificity of CMC. Each point shows the specific 51Cr release from 10  5 BN-EFB 
by 10  7 LABN aggressor cells 7 days after placement of BN skin grafts and represents the mean 
of five ieplicate samples of pooled cells from three rats,  +  1 SD (vertical lines). Symbo]s: [2, 
BN-EFB; II, Le-EFB; ©,  51Cr Le-EFB +  BN-EFB. Shaded area: mean 51Cr  release 4- 1 so 
from 51Cr BN-EFB and 51Cr Le-EFB incubated  7 1/2 hr without aggressor cells. 
rats survival of skin allografts may be significantly prolonged by administration 
of EAS  (29).  It  was  of interest,  therefore,  to  investigate  CMC  in  lymphoid 
tissues  of rats  manipulated  in  this  fashion.  7  days  after  placement  of  a  BN 
skin  graft,  recipients  of  all  three  groups showed significantly less  CMC  than 
normal  adult  rats  (Table  I).  Specific  51Cr release  by aggressor spleen  cells  of 
neonatally  thymectomized  or  cyclophosphamide-treated  recipients  did  not 
exceed the release caused by nonimmune spleen cells. Aggressor cells from 15- 
day-old  neonates  and  from  incompletely  thymectomized  graft  recipients  re- 30" 
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FIG. 3.  Effect of varying numbers of aggressor cells on specific  5lCr  release. Each point 
shows the specific  51Cr release from 10 5 BN-EFB incubated for 7 1/2 hr with increasing num- 
bers of aggressor cells and represents mean of six replicate samples of pooled cells from three 
rats, 4- 1 SD (vertical lines). Symbols: O, Le spleen cells from aUografted donors; O, Le non- 
immune spleen cells.  Shaded area:  51Cr release 4- 1 SD from target cells  (BN-EFB) without 
aggressor cells. 
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FIG. 4.  Kinetic study of CMC in spleens and lymph nodes of aHografted Le rats.  Each 
point shows the specific  51Cr release from 10 5 BN-EFB incubated for 7 1/2 hr with 10 7 Le 
spleen and lymph node cells and represents the mean of four replicate samples from each of 3 
to  10  rats,  -4-  1  SD  (vertical  lines).  Donors  of  aggressor  cells  were  grafted  with  BN 
skin.  Symbols:  C)--O,  Le-sensitized spleen cells;  [~--[::],  Le-sensitized lymph node cells. 
Shaded area:  Mean specific  51Cr release 4-  1 SD from 10 5 BN-EFB incubated with 107 Le 
spleen  or  lymph  node  cells  from  rats  inoculated  with  incomplete  Freund's  adjuvant 
(28 animals). 
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FIO.  5.  CMC in peripheral blood of allografted adult Le rats. Each point shows the specific 
~JCr release from 10 5 BN-EFB and represents the mean of five replicate samples of pooled cells 
from two or three animals, 4- 1 sp (vertical lines). Symbols: ©--O,  10 7 cells from allografted 
rats. Shaded area: mean specific 51Cr release 4- 1 sn from 10 5 BN-EFB and t0  7 nonimmune 
lymphoid cells (13 animals). 
TABLE  I 
Specific 51Cr Release  from BN-EFB* Incubated with Le Lymphoid Ceils 
Source of Le cells 
% specific  ~lCr release:~  -4- SD  Total cells  CL per 
Le spleen  Le lymph  per spleen  spleen§ 
cells  node cells  X l0  s  X 10  s 
Normal adult rats (21)[[  5.0  +  3.6  n.d.¶  4.0  0 
Adult allografted rats  (10)  32.2  -4-  11.4  47.1  -4-  11.2  3.0-5.0  1088 
15-day-old allografted rats  (3)  18.6  ~  1.1  --**  0.8-1.2  136 
Cyclophosphamide-treated atlo-  8.8  ±  2.7  0.7  3.0  114 
grafted adult rats (3) 
Neonatally thymectomized allo- 
grafted adult rats (5) 
Complete  8.0  ±  1.1  --**  4.0  93 
Incomplete  15.6  ±  3.8  --**  3.1  424 
* Embryonic fibroblasts. 
See Materials and Methods for definition. 
§CalcuIated  cytotoxic lymphocytes  (CL)  after  correction for  CL  in  normal  Le  spleen. 
Animals were compared 7 days after BN skin grafts. 
I1 Figures in parentheses indicate number of rats. 
¶  Not done, 
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leased about 50 % of the '5~Cr released by aggressor cells of untreated allografted 
adult rats. 
Based  on the  postulate  that  one aggressor cell  kills  one target  cell,  i.e.  the 
one-hit theory  (31, 32),  the number of CL per spleen was calculated.  In adult 
unmanipulated  Le  recipients  of allografts,  CL were  0.5 %  of lymph  node  cell 
suspensions and 0.3 % of suspensions of spleen cell and peripheral blood lympho- 
cytes tested at the height of CMC. In neonates, cyclophosphamide-treated and 
neonatally thymectomized adults,  CL per spleen were calculated to be 10 %  of 
these values (Table I). 
Effect of EAS on Allografted Le Neonates.--Litters of eight Le neonates were 
grafted on day 7 with BN skin. On the day of grafting, four cubs were injected 
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Fro.  6.  Effect of EAS on CMC in allografted Le neonates.  Each point shows the specifi 
5]Cr release from 105 BN-EFB and represents five replicate samples of cells from each of 3 to 
10 rats,  -4- 1 sD (vertical lines). Donors of aggressor cells were grafted with BN skin 7 days 
previously. Symbols:  •,  NLS (normal Le serum) ; ©, EAS  (enhancing antiserum).  Shaded 
area: mean specific 51Cr release 4- 1 SD from BN-EFB incubated  with cells from normal Le 
rats (21 animals). 
intraperitoneally  with  0.3 ml of EAS and four with 0.3 ml of NLS. From 5  to 
13 days later spleens and axillary lymph nodes of each animal were pooled and 
assayed for CMC (Fig. 6). Peak CMC in spleens of neonates injected with NLS 
occurred 7  and 8  days after grafting,  at  the  same  time  as it  was observed  to 
occur  in  allografted  unmanipulated  adult  rats.  By  contrast,  peak  CMC  in 
spleens  of neonates  injected  with  EAS  occurred on days  11  and  12,  3-4 days 
later  than  peak  activity  in  neonates  given  NLS.  The  level  of  CMC  in  Le 
neonates, as measured by specific ~lCr release, was only about 45 %  of that cal- 
culated in adult spleens.  At day 7 the level of CMC  in EAS-treated  neonates 
was reduced to about 50%  of the CMC found in neonates treated  with NLS, 
and to about 2(~30 % of the CMC calculated in lymphoid tissues of unmanipu- 
lated adults  (Figs. 4  and 6). 
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When  51Cr  BN-EFB  were  preincubated  in  LABN-EAS,  LABN-IgG,  and 
EIgG-~2~I, activity of aggressor cells was blocked (Fig.  7  a).  Blocking  was in- 
complete, and CMC was reduced to about 50% of the CMC observed with pre- 
incubation of NLS.  As EAS  was  diluted,  blocking was  less effective,  until no 
significant effect of EAS was noted when it was diluted 1 : 16. 
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FIG.  7.  Effect in vitro of blocking antibodies on 51Cr release from  target  cells  incubated 
with blocking antibodies. Each point shows specific 51Cr release from 10 5 BN-EFB and repre- 
sents the mean of five replicate samples,  4- 1 SD (vertical lines). BN-EFB target cells were 
incubated with normal serum or blocking antibodies for 45 min before addition of l07 aggressor 
cells.  (a)  Symbols: -*-,  BN-EFB  +  NLS  +  Le CL;  O-, BN-EFB  +  EAS  +  Le CL; 
--O--, BN-EFB +  NLS +  nonimmune Le cells; --C)--, BN-EFB +  EAS +  nonimmune  Le 
cells. Shaded area: mean specific 51Cr release -4- 1 SD from BN-EFB and nonimmune  lymphoid 
cells, without serum or antibodies. (b) Symbols: -*-,  BN-EFB  +  NLS  +  CL; -A-, BN- 
EFB +  EIgG-125I +  CL; -I1-, BN-EFB +  EAS IgG +  CL;  ---I---, BN-EFB +  NLS + 
nonimmune  Le cells; ---/k---, B  N-EFB +  EIgG-1251 +  nonimmune  Le cells; ---II---, BN-EFB 
+  EAS ]gG +  nonimmune  Le cells. Shaded area: same as above. 
Lymphocyte  suspensions  derived  from  nongrafted  control  rats  exhibited 
slight specific ~lCr release, about 6 %  when a  1 : 2 dilution of NLS was incubated 
with target  cells and 3 %  when higher dilutions of NLS  were used. When EAS 
was  preincubated  with  target  BN-EFB  and,  later,  when lymphoid cells from 
nonimmune rats were added,  there was a  specific release of 51Cr up to 7 %;  and 
this was statistically significantly greater  than the  release observed  in control 1310  CELL  IMMUNITY  IN  GRAI~'T  REJECTION  AND  ENHANCEMENT 
incubations  (Fig. 7 a). This specific release of ~lCr with EAS and normal lymph- 
oid cells was  consistently  observed  in five separate  trials.  Similar results  were 
observed  when  target  cells were preincubated  with  LABN-IgG,  but  not  with 
EIgG-125I  (Fig.  7  b). 
Preincubation  of  LABN  aggressor  cells  in  EAS,  in  LABN-IgG,  and  in 
TABLE  II 
Effect of NLS,*  EAS,  and  EIgG-125I  on  Specific Release  of  ~lCr by LABN  Aggressor  Cells 
Preincubation,  + with  (:~ specific S~Cr release 4- SD 
MEM  49.7  -4-  2.1 
0.5 ml NLS  47.7  ±  1.5 
0.5 ml EAS  46.6  4-  1.6 
0.5 ml (60 ng) EIgG-12aI  50.9  4-  2.5 
* NLS  =  normal Le serum; EAS  =  enhancing antiserum; EIgG-125I  =  enriched labeled 
IgG with enhancing activity; LABN =  Lewis anti-BN. 
:~ 5  X  10 T lymphoid cells from allografted Le recipients were incubated  for 30 min,  at 
37°C,  and  washed  two times.  107  cells,  in five assays for each group, were mixed with  105 
BN-EFB. 
TABLE  III 
Effect of HARTD  ou Specific Release of 5lCr by LABN  Aggressor  Cells 
%  inhibition  of  %  dead cells*  Preincubation*  with  specific 5lCr release 
HARTD §  66.1  24 
HARTD§ ~- C]]  96.7  91 
HARTD absorbed¶  0.0  18 
HARTD absorbed  +  C  5.0  16 
C  6.9  19 
* 10  v lymphoid cells from allografted Le rats  were incubated  for 45  rain,  at  37°C,  and 
washed two times before mixing with 105 BN-EFB. 
:~ As determined by staining with trypan blue. 
§ Horse antiserum  to rat  thoracic duct cells,  IgG fraction, absorbed  once with  1  X  109 
rat bone marrow cells. 
II Complement (C) used as fresh guinea pig serum diluted 1 : 2 with MEYL 
¶  Absorbed four times with 5 X  10  ~ rat thymus cells. 
EIgG-a~5I  did  not  block  CMC  in  vitro  (Table  II),  nor  did  NLS  display  any 
blocking activity under  these conditions. 
By contrast,  when HARTD  IgG,  absorbed  with rat  bone  marrow  cells, was 
first incubated with aggressor cells and then washed out before mixing aggressor 
and target cells, inhibition of CMC  was significant (Table III). In the presence 
of complement, the same antibody preparation apparently killed aggressor cells, 
and CMC  was completely inhibited. If HARTD  IgG was absorbed with thymo- 
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DISCUSSION 
The data gathered in this report support three broad conclusions. First, CMC 
can be measured quantitatively in the lymphoid tissues and peripheral blood of 
allografted adult rats, and displays a response that resembles the rise and fall 
of antibody on a first exposure to antigen. CMC was first detected in draining 
lymph nodes 5  days after grafting, peaked 2-3  days later,  and promptly re- 
turned to background levels by day 9. Its appearance preceded any visible gross 
changes in the skin allograft and coincided with the earliest mononuclear cell 
infiltrations as determined by histologic examination (33). A period of 5  days 
was  needed  for  CMC  to  be  detectable,  and  presumably  this  time  interval 
allowed for processing  of  alloantigens,  recognition by  antigen-reactive  cells, 
conversion to effector elements, and accumulation of sufficient numbers to be 
assayed. The rapid decline of CMC in lymphoid tissues of the grafted rat might 
have been the result of several events, e.g., the convention of CL  and  their 
destruction in the dying graft, the expulsion of histoincompatible AgB antigens 
from the host, and the subsequent absence of AgB  antigens, which no longer 
drove  the  cellular  immune  response  to  recruit  and/or  reproduce  additional 
effector elements. The prolonged persistence of CMC,  described by Brunner 
et al. (4), may reflect the difference between a proliferating neoplastic graft and 
a normal tissue graft. 
The  kinetics  of  CMC  in  the  lymphoid  tissues  and  peripheral  blood were 
similar.  Unfortunately,  measurements  of  CMC  in  lymphoid  tissues  and  in 
peripheral blood were made in two different groups of rats. It was not possible, 
therefore, to relate precisely the temporal development of CMC  in these two 
anatomic  sites,  or  to  state  if  CL  migrated  from  lymphoid  tissues  into  the 
blood, or if CL were activated peripherally and congregated in lymphoid tissues. 
Nor was it possible to ascertain if the CL in the peripheral blood were  related to 
circulating activation lymphocytes described by Hersh et al.  (34). 
The CMC assayed in this report belonged to the category first described by 
Snell et al. (35) a decade ago, and later characterized more carefully by Wilson 
et al.  (36) and Brunner and his colleagues (3-5,  14,  16).  These latter workers 
demonstrated a direct killing action by thymus-derived cells against target cells 
with histoincompatible antigens. Both conventional-type antibody and comple- 
ment did not play any role in the cytotoxic activities described. Our observa- 
tions with rat cells coincided with  their findings for mouse systems. Neither 
alloantibody nor complement contributed to the killing  action of CL  in  our 
assay.  Furthermore,  on  a  semilogarithmic scale,  a  nearly straight-line  dose- 
response curve depicted the action of an increasing number of aggressor cells on 
a fixed number of target cells over a wide range, and no toxic factor was detected 
in the medium after interaction between CL and histoincompatible targets. 
The second conclusion issuing from our data was that  allografted neonatal 
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exhibited a  reduced capacity for CMC.  Calculations of CL in these kinds  of 
rats, based on a  one-hit theory (17,  34), disclosed that their lymphoid tissues 
contained a fraction of the number of CL enumerated in the lymphoid tissues of 
allografted unmanipulated adult rats. In the latter animals CL were calculated 
to be 0.5 % in lymph nodes and 0.3 % in spleens and peripheral blood. The cal- 
culated  number  tallies  well  with  the  calculated  number  of  effector cells  in 
lymphoid tissues of guinea pigs  (37)  and in peripheral blood of humans  (38) 
with delayed hypersensitivity. Henney determined a similar small number per 
II-2 antigen in sensitized mice  (18),  as did Brunner (39)  and Cerottini et  al. 
(16), employing a tumor graft model. Wilson et al. calculated 1-3 % of reactive 
cells in a mixed lymphocyte culture system (36) by measuring uptake of thymi- 
dine-3H. This calculated number is two- to three-fold higher than the number of 
CL in a cytotoxic assay and is based on a different process, one of synthesis of 
nuclear DNA,  which may not be equivalent to effector aggressor cells in  an 
attack system. 
The third conclusion derived from our data was that EAS  and LABN-IgG 
delayed the development of CMC in rats with reduced immunologic capacity, 
e.g., in neonates and cyclophosphamide-treated or neonatally thymectomized 
adult rats. The period of deferral was about 4 days and appeared to be due to 
blockade of antigenic sites of the target graft. We have shown elsewhere that 
EAS and LABN-IgG were bound to allogeneic skin grafts and remained bound 
for 3-4 days  (29).  Those  data  and  the  ones reported here suggest  "afferent 
blockade" in vivo. In vitro, "efferent blockade" apparently is operative simply 
because of the temporal design of the cytotoxic test. Blocking antibodies were 
bound to antigenic sites and  thus prevented CL from attacking target cells. 
Preincubation of CL  with EAS and LABN-IgG had no effect on release of 51Cr 
from target cells. This result was not in accord with the reports of inhibition of 
CMC by blocking antibodies described by the HellstrSms and their coworkers 
(40-42).  By contrast, HARTD  IgG  containing xenogeneic  antibodies  to  rat 
lymphocytes effectively inhibited CMC without complement. 
In  one  series  of  experiments  there  was  evidence that  blocking  antibodies 
bound to target antigens and normal  (unsensitized)  allogeneic lymphoid cells 
were slightly but significantly toxic to target cells.  We cannot be certain that 
this is biologically important and, if it is, what mechanism might be involved. 
Perlmann and his colleagues have reported minor cytotoxic activity by normal 
human lymphocytes that have been activated by antigen-antibody complexes 
(6, 43). The complexes consisted of both xenogeneic chicken erythrocytes and 
rabbit antibodies. It is moot if their model can be related to our data with EAS 
and normal lymphocytes. 
One  can  only speculate  why  different  schedules  of  immunization  elicited 
different levels of CMC. A single skin or renal graft was more effective than a 
single infusion of spleen cells or repeated skin and spleen cell grafts. Perhaps 
there was antigenic overload with the latter regimen, or perhaps BN spleen cells 
in Le recipients exerted a deleterious effect upon the development and expres- HANS-HARTMUT PETER  AND  JOSEPH D.  FELDMAN  1313 
sion of CMC. It was also possible that measurement  of CMC 7 days after the 
last of several grafts was carried out on a day that was not optimal for CMC. 
SUMMARY 
Cell-mediated cytotoxicity (CMC) in spleens and lymph nodes of allografted 
rats was determined by release of 51Cr from labeled target cells incubated with 
aggressor lymphoid cells.  CMC was first detected in grafted adult rats on day 
5, peaked on days 7 and 8, and declined rapidly to background levels by days 
9 to 11. In allografted neonates and in cyclophosphamide-treated or neonatally 
thymectomized adults  CMC  was  a  fraction of that  observed in normal  adult 
rats.  Enhancing  antibodies  deferred  in  vivo  peak  activity  of  CMC  in  allo- 
grafted  neonates  for 3-4  days,  and  blocked  in  vitro  the  action  of  aggressor 
lymphocytes by binding to target cells. Enhancing antibodies had no effect on 
the  cytotoxicity of  aggressor  cells,  but  horse  antibodies  to  rat  thoracic  duct 
cells inhibited in vitro CMC of aggressor cells. 
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